Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

The research also notes that M&A deals have been the primary way in which big pharma companies secure these orphan drug designations, with very few rare disease drugs being developed in-house.